Media coverage about Cerecor (NASDAQ:CERC) has trended somewhat positive on Sunday, according to Accern Sentiment. Accern scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cerecor earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.8927318879608 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Cerecor (NASDAQ:CERC) traded up $0.04 during trading hours on Friday, reaching $2.74. 479,728 shares of the company traded hands, compared to its average volume of 859,399. The company has a market cap of $71.39, a P/E ratio of 274.27 and a beta of 2.95. Cerecor has a one year low of $0.34 and a one year high of $4.25.
Several analysts have recently issued reports on CERC shares. ValuEngine upgraded shares of Cerecor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 7th. TheStreet upgraded shares of Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th.
COPYRIGHT VIOLATION NOTICE: “Cerecor (CERC) Receiving Somewhat Positive News Coverage, Report Shows” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/14/cerecor-cerc-receiving-somewhat-positive-news-coverage-report-shows.html.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
What are top analysts saying about Cerecor? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cerecor and related companies.